Mark Stein, PhD, ABPP

Personal Statement

I am clinical psychologist and a Professor of Psychiatry and Pediatrics, and a clinical researcher specializing in ADHD throughout the lifespan. I direct the PEARL Clinic (Program to enhance ​attention, regulation, and learning) at Seattle Children’s. The PEARL Clinic is based on a multidisciplinary and collaborative care model which works closely with PCP’s who refer families to PEARL for evaluation and access to  our behavioral group treatment programs and treatment recommendations.   The PEARL clinic also provided multidisciplinary training for psychologists, psychiatrists, pediatricians, family medicine physicians, and medical students. The majority of my clinical work involves  diagnostic evaluations and consultations  for the parents, referring physician, and schools. My research emphasis is on personalizing ADHD treatment, and determining how best to combine and sequence interventions throughout the lifespan for  individuals with ADHD.    I have  assisted in the development of several stimulant  and non stimulant medications, and participated in many clinical trials. Currently, we are   conducting a study  for parents with ADHD who have young children with ADHD symptoms where we are treating the parent with medication  and  behavioral parent training or behavior parent training. I am also investigating the relationship between genetic factors and ADHD treatment response. Other areas of interest include sleep problems and overlap with ADHD,  and novel treatments such as Trigeminal Nerve Stimulation (TNS) and augmentation strategies such as mindfulness and physical exercise or activity level.


Medical school: Southern Illinois University - Carbondale
Fellowship: MacLean Center for Clinical Medical Ethics, Chicago

Department Affiliations

Other Affiliations

PEARL Clinic, Director – Seattle Children’s Hospital
Training Clinic


Center for Child Health, Behavior, and Development


Brotman Baty Institute

Recent Publications

Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial.
(2024 May 28)
Eur Urol
Lara PN Jr, Tangen C, Heath EI, Gulati S, Stein MN, Meng M, Alva AS, Pal SK, Puzanov I, Clark JI, Choueiri TK, Agarwal N, Uzzo R, Haas NB, Synold TW, Plets M, Vaishampayan UN, Shuch BM, Lerner S, Thompson IM Jr, Ryan CW

Expert Consensus Statement for Telepsychiatry and Attention Deficit Hyperactivity Disorder.
(2024 May 20)
CNS Spectr
Hong J, Mattingly GW, Carbray JA, Cooper TV, Findling RL, Gignac M, Glaser PE, Lopez FA, Maletic V, McIntyre RS, Robb AS, Singh MK, Stein M, Stahl SM

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
(2024 Apr 11)
J Immunother Cancer 12(4):
Atkins MB, Jegede OA, Haas NB, Mcdermott DF, Bilen MA, Stein M, Sosman J, Alter R, Plimack ER, Ornstein MC, Hurwitz M, Peace DJ, Einstein D, Catalano PJ, Hammers H, Regan MM

Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes.
(2024 Feb 28)
Prostate Cancer Prostatic Dis
Zorko NA, Makovec A, Elliott A, Kellen S, Lozada JR, Arafa AT, Felices M, Shackelford M, Barata P, Zakharia Y, Narayan V, Stein MN, Zarrabi KK, Patniak A, Bilen MA, Radovich M, Sledge G, El-Deiry WS, Heath EI, Hoon DSB, Nabhan C, Miller JS, Hwang JH, Antonarakis ES

A new schizophrenia screening instrument based on evaluating the patient's writing.
(2024 Apr)
Schizophr Res 266(): 127-135
Peng Z, Li Q, Liu X, Zhang H, Luosang-Zhuoma, Ran M, Liu M, Tan X, Stein MJ

Show complete publication list »
Edit Profile